Influenza B virus, split virion
Highest phase reached
Approved
Drug type
Vaccine component
First approval year
2009
- First approval year
- 2009
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Vaccine component
- Drug name
- Influenza B virus, split virion
- influenza b virus split virion component of idflu
- influenza b virus split virion component of intanza
- Influenza b virus, split virion component of idflu
- Influenza b virus, split virion component of intanza
- influenza b virus split virion
- Influenza b virus, split virion
- ChEMBL ID
- CHEMBL6068386
- First in class
- No
- Orphan designation
- No
- Drug name stem
- vir-
- Condition
- Vaccination
- Highest recorded phase
- 4
- Condition identifier
- EFO:0004292
- Subject identifier
- D014611
- Condition
- Influenza, Human
- Highest recorded phase
- 4
- Condition identifier
- EFO:0007328
- Subject identifier
- D007251
- Condition identifier
- EFO_0007328
- Condition identifier
- EFO_0007411
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005812
- Highest recorded phase
- 4
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (22)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months
- Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe
- Evaluate Safety of GCFLU® Administered Intramuscularly in Healthy Vietnamese Volunteer Aged From 3 Years Old
- Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.
- Immunogenicity and Safety of a Quadrivalent Influenza Vaccine Given by Intramuscular Route in Subjects Aged 18 to 60 Years
- Immunogenicity and Safety of Butantan Quadrivalent Influenza Vaccine (Split Virion, Inactivated) in Infants and Children .
- Influenza Vaccination in Fibromyalgia Patients
- Influenza Vaccination in Hemodialysis Patients and Renal Transplant Recipients
- Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Population Aged 3 Years and Older
- Phase 3 Safety and Immunogenicity Study of aQIV in Elderly Adults
- Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine
- Proteomic Profiling for Influenza
- Safety and Immunogenicity of Trivalent Split Influenza Vaccine Using the Strain Composition 2007/2008
- Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age
- Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea
- Study on Heterologous Prime-boost of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine
- Study to Evaluate Immunogenicity and Safety of a High-Dose Influenza Vaccine in Adults 50 Through 64 Years of Age
- The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.
- The Objectives of This Study Are Study the Immunogenicity and Safety of the Flu-M [Inactivated Split Influenza Vaccine], vs. the Ultrix® Inactivated Split Influenza Vaccine, in Volunteers Who Are Over 60 Years Old
- The Objectives of This Study Are Study the Safety, Reactogenicity and Obtain Preliminary Data on the Immunogenicity of Flu-M Quadro, 4-valent Inactivated Split Influenza Vaccine, in Healthy Volunteers